208 related articles for article (PubMed ID: 33515299)
21. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Redelman-Sidi G; Michielin O; Cervera C; Ribi C; Aguado JM; Fernández-Ruiz M; Manuel O
Clin Microbiol Infect; 2018 Jun; 24 Suppl 2(Suppl 2):S95-S107. PubMed ID: 29427804
[TBL] [Abstract][Full Text] [Related]
22. Sequential treatment of progressive multifocal leukoencephalopathy with intravenous immunoglobulins and pembrolizumab.
Boesl F; Allers K; Herm J; Scheider T; Franke C
J Neurovirol; 2022 Apr; 28(2):335-338. PubMed ID: 35320511
[TBL] [Abstract][Full Text] [Related]
23. Immunology of progressive multifocal leukoencephalopathy.
Jelcic I; Jelcic I; Faigle W; Sospedra M; Martin R
J Neurovirol; 2015 Dec; 21(6):614-22. PubMed ID: 25740538
[TBL] [Abstract][Full Text] [Related]
24. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
25. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
26. Novel treatments for progressive multifocal leukoencephalopathy.
Bennett KM; Fernandes PM
Br J Hosp Med (Lond); 2020 Jul; 81(7):1-9. PubMed ID: 32730143
[TBL] [Abstract][Full Text] [Related]
27. Advances in Treatment of Progressive Multifocal Leukoencephalopathy.
Bernard-Valnet R; Koralnik IJ; Du Pasquier R
Ann Neurol; 2021 Dec; 90(6):865-873. PubMed ID: 34405435
[TBL] [Abstract][Full Text] [Related]
28. Prevention and therapy of JC polyomavirus-mediated progressive multifocal leukoencephalopathy - a realistic possibility?
Jelcic I; Combaluzier B; Jelcic I; Sospedra M; Grimm J; Martin R
Swiss Med Wkly; 2017; 147():w14520. PubMed ID: 29120025
[TBL] [Abstract][Full Text] [Related]
29. JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.
Koralnik IJ; Du Pasquier RA; Letvin NL
J Virol; 2001 Apr; 75(7):3483-7. PubMed ID: 11238876
[TBL] [Abstract][Full Text] [Related]
30. Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy.
Jelcic I; Combaluzier B; Jelcic I; Faigle W; Senn L; Reinhart BJ; Ströh L; Nitsch RM; Stehle T; Sospedra M; Grimm J; Martin R
Sci Transl Med; 2015 Sep; 7(306):306ra150. PubMed ID: 26400911
[TBL] [Abstract][Full Text] [Related]
31. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
32. The human JC polyomavirus (JCPyV): virological background and clinical implications.
Hirsch HH; Kardas P; Kranz D; Leboeuf C
APMIS; 2013 Aug; 121(8):685-727. PubMed ID: 23781977
[TBL] [Abstract][Full Text] [Related]
33. Advances in the management of PML: focus on natalizumab.
Fox R
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S33-7. PubMed ID: 22123933
[TBL] [Abstract][Full Text] [Related]
34. Progressive multifocal leukoencephalopathy - epidemiology, immune response, clinical differences, treatment.
Snopková S; Štourač P; Fašaneková L; Mihalčin M; Havlíčková K; Svačinka R; Volfová P; Snopek P; Husa P
Epidemiol Mikrobiol Imunol; 2019; 68(1):24-31. PubMed ID: 31181949
[TBL] [Abstract][Full Text] [Related]
35. A loop-mediated isothermal amplification assay for the detection and quantification of JC polyomavirus in cerebrospinal fluid: a diagnostic and clinical management tool and technique for progressive multifocal leukoencephalopathy.
Kinoshita H; Nakamichi K; Lim CK; Takayama-Ito M; Wang L; Iizuka I; Kurane I; Saijo M
Virol J; 2018 Aug; 15(1):136. PubMed ID: 30170628
[TBL] [Abstract][Full Text] [Related]
36. A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus.
Ramadhani P; Bramantono B; Sedana MP
Acta Med Indones; 2018 Apr; 50(2):151-158. PubMed ID: 29950535
[TBL] [Abstract][Full Text] [Related]
37. An autopsy case of progressive multifocal leukoencephalopathy after rituximab therapy for malignant lymphoma.
Muto R; Sugita Y; Momosaki S; Ito Y; Wakugawa Y; Ohshima K
Neuropathology; 2019 Feb; 39(1):58-63. PubMed ID: 30511425
[TBL] [Abstract][Full Text] [Related]
38. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Bauer J; Gold R; Adams O; Lassmann H
Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
[TBL] [Abstract][Full Text] [Related]
39. Severe Progressive Multifocal Leukoencephalopathy (PML) and Spontaneous Immune Reconstitution Inflammatory Syndrome (IRIS) in an Immunocompetent Patient.
Krey L; Raab P; Sherzay R; Berding G; Stoll M; Stangel M; Wegner F
Front Immunol; 2019; 10():1188. PubMed ID: 31191548
[No Abstract] [Full Text] [Related]
40. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
